GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
136 articles on this topic
-
Does Semaglutide Cause Cancer? What Studies Show
Human studies have not established that semaglutide causes cancer. The thyroid warning remains, and lower cancer rates in some studies are not proof of prevention.
-
Tirzepatide and Kidney Disease: Risks and Evidence
Kidney disease does not automatically rule out tirzepatide. The key questions are dehydration risk, recent kidney tests and what the newer studies actually measured.
-
TrumpRx GLP-1 Prices: Beyond the Starting Price
Wegovy pills start at $149 and some pen offers at $199. Later fills, strength and eligibility determine the bill that follows.
-
503B Outsourcing Facility: What the Term Means
A 503B facility can prepare compounded medicines for clinic stock under federal manufacturing rules. Its registration describes the facility, not a review of each medicine.
-
10 Questions to Ask Doctor About Tirzepatide
A tirzepatide visit is mostly about fit: the provider needs a clear picture of medical history, medicines, pregnancy plans, digestion, and upcoming procedures. These ten questions explain what matters and why.
-
SURMOUNT-1 Results: What the Trial Actually Found
SURMOUNT-1 followed 2,539 adults without diabetes for 72 weeks. Average weight change ranged from -15.0% to -20.9% with tirzepatide, compared with -3.1% with placebo.
-
15 Percent Weight Loss: What the Numbers Show
At 220 pounds, 15 percent is 33 pounds. Trials also measured waist, blood pressure, blood sugar, sleep, pain and physical function—but those group averages are not a personal forecast.
-
Who Discovered GLP-1? The Team Behind the Medicine
No single scientist discovered GLP-1. The answer is a chain of teams that found the gene, identified the working hormone, tested what it did, and designed medicines that lasted long enough to use.
-
Zepbound Prescribing Information, Explained
The current label is revised August 2026. It covers two uses, a weekly dose ladder, two absolute contraindications, the boxed thyroid warning, common stomach side effects, pregnancy, and four delivery formats.
-
FDA Tentative Approval: What It Means
FDA tentative approval means an application has cleared the scientific review needed for approval, but a legal barrier still prevents U.S. marketing. It is a real milestone, not permission to sell the drug.
-
Tirzepatide News Update: September 2026
The month's biggest change is narrow but important: Mounjaro gained a cardiovascular-risk indication for certain adults with type 2 diabetes. Here is what else changed—and what did not.
-
Does Medicare Cover GLP-1 for Weight Loss? It Can
Some Medicare patients now qualify for a $50 monthly GLP-1 prescription. The Bridge has specific product and health requirements, and compounded prescriptions are outside it.
-
MOTS-c and Retatrutide: No Evidence for a Stack
No published study has tested MOTS-c and retatrutide together. Retatrutide cannot be compounded for patient care, while MOTS-c is a separate prescription discussion with much thinner human evidence.
-
Semaglutide Meal Plan: A Simple Day Structure
A useful plan is flexible: smaller meals, protein early, fiber at a tolerable pace, and fluids across the day. This sample day uses portion ranges rather than a calorie rule.
-
Compounded Semaglutide Side Effects: What Changes?
Most compounded semaglutide side effects come from semaglutide itself. Compounding can add separate risks involving concentration, added ingredients, ingredient form, sterility, and labeling.
-
Semaglutide Pronunciation: How to Say It
Semaglutide is pronounced sem-a-GLOO-tide. The middle is easier once you know where the stress goes and why several related medicine names share the same ending.
-
Tesamorelin vs Tirzepatide: Which Fits Which Goal?
Tesamorelin and tirzepatide can both change fat-related measures, but they answer different clinical questions. One has narrow evidence for deep abdominal fat in adults with HIV lipodystrophy; the other was studied for total body weight.
-
503B Bulks List GLP-1: Still a Proposal
FDA proposes leaving three GLP-1 ingredients off the 503B bulks list. Comments closed July 30; patient-specific prescriptions follow separate rules.
-
Semaglutide Type 1 Diabetes: Guidance Has Limits
New 2026 guidance treats GLP-1 therapy as a possible obesity tool for some adults with type 1 diabetes, not as a replacement for insulin. The evidence is promising but small, and semaglutide is not approved to treat type 1 diabetes.
-
Tirzepatide Meal Plan: Small Meals, Protein First
A useful tirzepatide meal plan is smaller and steadier: protein first, produce and fiber as tolerated, and fluids between meals. It should bend around appetite and side effects, not force a calorie target.
Page 1 of 7 · 136 articles